These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 11786103

  • 1. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P.
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [Abstract] [Full Text] [Related]

  • 2. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO, Alaupovic P, Tavella M, Knight-Gibson C.
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [Abstract] [Full Text] [Related]

  • 3. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P.
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [Abstract] [Full Text] [Related]

  • 4. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.
    Hughes TA, Gaber AO, Amiri HS, Wang X, Elmer DS, Winsett RP, Hathaway DK, Hughes SM, Ghawji M.
    Metabolism; 1994 Mar; 43(3):333-47. PubMed ID: 8139482
    [Abstract] [Full Text] [Related]

  • 5. Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure.
    Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P.
    Miner Electrolyte Metab; 1992 Mar; 18(2-5):199-202. PubMed ID: 1465058
    [Abstract] [Full Text] [Related]

  • 6. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
    Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H.
    Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
    [Abstract] [Full Text] [Related]

  • 7. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product.
    Alaupovic P, Wang CS, McConathy WJ, Weiser D, Downs D.
    Arch Biochem Biophys; 1986 Jan; 244(1):226-37. PubMed ID: 3080947
    [Abstract] [Full Text] [Related]

  • 8. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
    Yiğitoğlu MR, Polat MF, Akçay F, Ari Z, Uyanik BS, Ozilgili HM.
    Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
    [Abstract] [Full Text] [Related]

  • 9. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
    Wang CS, Alaupovic P, Gregg RE, Brewer HB.
    Biochim Biophys Acta; 1987 Jul 13; 920(1):9-19. PubMed ID: 3109493
    [Abstract] [Full Text] [Related]

  • 10. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H.
    Arterioscler Thromb Vasc Biol; 2005 Dec 13; 25(12):2615-22. PubMed ID: 16195474
    [Abstract] [Full Text] [Related]

  • 11. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.
    Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T.
    Kidney Int Suppl; 1999 Jul 13; 71():S227-8. PubMed ID: 10412783
    [Abstract] [Full Text] [Related]

  • 12. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar 13; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Anomalies of lipoprotein metabolism in chronic renal insufficiency].
    Lacour B, Massy ZA, Jungers P, Drueke T.
    Nephrologie; 1993 Mar 13; 14(2):75-90. PubMed ID: 8327031
    [Abstract] [Full Text] [Related]

  • 16. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
    Shoji T, Hatsuda S, Tsuchikura S, Kimoto E, Kakiya R, Tahara H, Koyama H, Emoto M, Tabata T, Nishizawa Y.
    Atherosclerosis; 2009 Dec 13; 207(2):579-84. PubMed ID: 19540497
    [Abstract] [Full Text] [Related]

  • 17. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
    Ruel IL, Lamarche B, Mauger JF, Badellino KO, Cohn JS, Marcil M, Couture P.
    Arterioscler Thromb Vasc Biol; 2005 Dec 13; 25(12):2600-7. PubMed ID: 16224048
    [Abstract] [Full Text] [Related]

  • 18. Effects of omega-3 fatty acids on intravascular lipolysis of very-low-density lipoproteins in humans.
    Kasim-Karakas SE, Herrmann R, Almario R.
    Metabolism; 1995 Sep 13; 44(9):1223-30. PubMed ID: 7666799
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure.
    Sentí M, Romero R, Pedro-Botet J, Pelegrí A, Nogués X, Rubiés-Prat J.
    Kidney Int; 1992 May 13; 41(5):1394-9. PubMed ID: 1614054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.